RecruitingPhase 2NCT06123338

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

Studying Adenocarcinoma of the cervix uteri

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Memorial Sloan Kettering Cancer Center
Principal Investigator
Yelena Janjigian, MD
Memorial Sloan Kettering Cancer Center
Intervention
Pembrolizumab(drug)
Enrollment
49 target
Eligibility
18 years · All sexes
Timeline
20242027

Study locations (10)

Collaborators

Genentech, Inc. · Merck Sharp & Dohme LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06123338 on ClinicalTrials.gov

Other trials for Adenocarcinoma of the cervix uteri

Additional recruiting or active studies for the same condition.

See all trials for Adenocarcinoma of the cervix uteri

← Back to all trials